Banner Alzheimer's Institute to lead groundbreaking prevention trial
The head of the National Institutes for Health (NIH), Francis Collins, announced that Banner Alzheimer’s Institute (BAI) would receive a $16 million grant from NIH that will help fund Alzheimer’s prevention research led by BAI. This research will be the first-ever prevention trial in healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history.
At the same time, BAI announced their industry partner for this Alzheimer’s Prevention Initiative trial, Genentech, and their experimental treatment called crenezumab. In addition to the $16 million grant from NIH for this research, Genentech will provide $69 million and the Banner Alzheimer’s Foundation will provide $15 million, totaling $100 million to support this groundbreaking study.
The trial is designed to determine whether the drug can reduce participants’ chances of developing the disease’s disabling and irreversible symptoms, preserve memory and thinking abilities and slow the progression of Alzheimer’s biomarkers. The study will span two countries and help launch a new era of prevention research in the urgent fight against Alzheimer’s.
Eric M. Reiman, MD and Pierre N. Tariot, MD from BAI lead the broader initiative, and they also will be leading the trial in close cooperation with Genentech’s research and clinical team and a Colombian team. Together, these three groups designed the study with input from other prominent scientists and NIH and regulatory officials.
“We are grateful for the chance to evaluate such a promising prevention treatment,” said Dr. Reiman, BAI Executive Director. “We have tried to design the study in a way that might bring the field closer to ending Alzheimer’s before another generation is lost.”
"Clearly, this research led by BAI is further evidence of Banner’s emergence as a national health care leader and a matter of great pride for all of us," said Banner President and CEO Peter S. Fine.
About 5.4 million Americans are living with Alzheimer’s today, a number expected to top 7.7 million by 2030. Globally, the disease and other dementias are expected to affect nearly 66 million by then.